©2025 Stanford Medicine
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Not Recruiting
Trial ID: NCT02462486
Purpose
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Official Title
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)
Stanford Investigator(s)
Theodore Leng, MD, FACS
Associate Professor of Ophthalmology (Ophthalmology Research/Clinical Trials) and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (MSD)
Eligibility
Inclusion Criteria:
* Diagnosis of age-related macular degeneration in at least 1 eye
* Best corrected visual acuity of 20/40 to 20/320 in the study eye
* Best corrected visual acuity of 20/200 or better in the non-study eye
Exclusion Criteria:
* History of vitrectomy, macular surgery, or glaucoma surgery in the study eye
* Cataract or refractive surgery in the study eye within the last 3 months
Intervention(s):
drug: abicipar pegol
drug: ranibizumab
other: sham procedure
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305